2026-06-01T19:30:51Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/87972024-03-14T11:52:07Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

Aldred, Jason Anca-Herschkovitsch, Marieta Antonini, Angelo Bajenaru, Ovidiu Bourgeois, Paul Cubo Delgado, Esther Davis, Thomas L. Iansek, Robert Kovács, Norbert Kukreja, Pavnit Onuk, Koray Pontieri, Francesco E. Robieson, Weining Siddiqui, Mustafa S. Simu, Mihaela Standaert, David G. Chaudhuri, K. Ray 5-2-1 Criteria for advanced PD Dyskinesia LCIG Levodopa Levodopa-carbidopa intestinal gel Off time Parkinson’s disease Aim: A Delphi expert consensus panel proposed that fulfilling ≥1 of the ‘5-2-1 criteria’ (≥five-times daily oral levodopa use, ≥two daily hours with ‘Off’ symptoms or ≥one daily hour with troublesome dyskinesia) suggests advanced Parkinson’s disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD – a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE) – is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa–carbidopa intestinal gel (LCIG) for advanced PD. Results: This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill ≥1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion: In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment. 2024-03-11 2024-03-11 2020-09 info:eu-repo/semantics/article 1758-2024 http://hdl.handle.net/10259/8797 10.2217/nmt-2020-0021 1758-2032 eng Neurodegenerative Disease Management. 2020, V. 10, n. 5, p. 309-323 https://doi.org/10.2217/nmt-2020-0021 http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional Future Medicine